.png)
.png)
Latest news from BIA
BIA exchanges member directories with Japanese leader in regenerative medicine
The UK Bioindustry Association (BIA) has exchanged member directories with The Forum for Innovative Regenerative Medicine (FIRM).
BIA respond to written ministerial statement on continuity of supply in a no-deal Brexit
Steve Bates OBE, Chief Executive of the BIA said: “I ask all companies that are seeking to use the Government procured supply routes to import and export medicines in the event of a no-deal to register their interest immediately. This is best done by replying to the communication from the Department of Health yesterday. This is a key step to enable companies to book and purchase government procured ferry space -as details of it emerge- in the weeks ahead.
UK Biotech raises £869 million in the year to 31 August
UK biotech companies are continuing to raise significant new funds despite investment across all sectors slowing, new data from the UK BioIndustry Association (BIA) and Informa Pharma Intelligence published today shows.
BIA responds to government announcement of significant cash funding to support scaling life sciences companies
Steve Bates OBE, Chief Executive of the UK BioIndustry Association said: "The UK life science ecosystem leads Europe in investment and is the world’s third global cluster in innovative life sciences. It’s great to see the Prime Minister has reaffirmed the government’s commitment to the UK life science industrial strategy to grow companies to scale in the UK. UK based entrepreneurs share his ambition to make this a key and vibrant sector of the UK’s economy going forward.
BioBeat19: Accelerating cell and gene therapy hosted by BioBeat
The cell and gene therapy sector is expanding fast, bringing undreamt of opportunities for scientists, entrepreneurs, innovators and investors. I hope you will join us for BioBeat19: Accelerating cell and gene therapy hosted by BioBeat in conjunction with GSK and Stevenage Bioscience Catalyst at GSK Stevenage.
MedAnnex begins cell line development at FUJIFILM Diosynth
Edinburgh-based biotechnology company MedAnnex today announced that cell line development for the generation of its anti-Annexin A1 antibodies is under way, at FUJIFILM Diosynth Biotechnologies’ (Fujifilm) Billingham, UK site.
Cellexus go global with new distribution network
Biotech company, Cellexus International Ltd, have increased their distributor network to bring their CellMaker bioreactor range to a global market.
Dosing Complete In Phase I Clinical Trial Of Ultra-Rapid Acting Insulin Product Candidate AT247 For Diabetes
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces completion of dosing and all patient visits in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247.
CEO Update|Monday 14 October
The weather may have caused maximum disruption in Japan this week, but not for biotech.
BIA meets FIRM in Japan
At a ceremony last Friday at BIO Japan in Yokohama, the BIA and the Japanese Forum for Innovative Regenerative Medicine (FIRM) exchanged directories of our members operating in the Cell and Gene Therapy space. This exciting new business tool springs from a partnership that was cemented with the signing of a Memorandum of Understanding between the BIA and FIRM earlier in the year. On our side, the work is led by the Cell and Gene Therapy Advisory Committee (CGTAC).
Overcoming the barriers to cell and gene therapies
The last decade has seen significant scientific developments in cell therapies, gene therapies and tissue engineered products, collectively described as ATMPs (Advanced Therapy Medicinal Products). The impact of such treatments could be transformational. As such, we believe it is crucially important to support the sector as it navigates the complex clinical, regulatory, manufacturing, and pricing environments in which it operates.
CEO Update|Monday 07 October 2019
With weeks to go until the 31 Oct Brexit deadline, this week Prime Minister Boris Johnson outlined his latest Brexit proposals, focussed on alternative solutions to the Irish border question.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector, BIA update: January - April 2018
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from January to April 2018.
Biotech Financing Update: December 2017 to February 2018
The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018.
Pipeline Progressing: The UK's Global Bioscience Cluster in 2017
A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.
BIA Best practice guide for communicating R&D
Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.
